journal article Open Access Mar 23, 2026

Multiple consecutive daily therapeutic plasma exchange using exclusively albumin replacement fluid in low bleeding risk patients is associated with only rare and mild bleeds

View at Publisher Save 10.1111/trf.70159
Abstract
Abstract

Background
Therapeutic plasma exchange (TPE) using exclusively albumin replacement fluid depletes coagulation factors, particularly fibrinogen, and concerns about performing multiple consecutive daily procedures due to iatrogenic bleeding exist. Fibrinogen testing to guide bleeding risk stratification is vague. We characterize our experience of changing our standard clinical practice by performing up to five consecutive daily TPE using exclusively albumin replacement fluid in conjunction with halting empiric coagulation testing (including fibrinogen testing) and fibrinogen supplementation.


Methods
In this 5‐year prospectively monitored experience, patients received 3–5 consecutive daily TPE using exclusively albumin replacement fluid. Patients with active bleeding, personal or family bleeding history, therapeutic anticoagulant or antiplatelet drugs, thrombocytopenia, or major interventional procedure within 24 h of TPE did not receive this updated treatment plan. Coagulation testing (including fibrinogen testing) was not ordered prior to any TPE. Events of interest were bleeding within 72 h after any TPE procedure.


Results
Overall, 228 unique patients had a total of 264 treatment series with a total of 1351 TPE performed. Sixty‐eight patients had 84 series, 101 patients had 116 series, and 59 patients had 64 series with 3, 4, and 5 consecutive daily TPE, respectively. Fourteen early and minor bleeds, predominantly central venous catheter‐associated, occurred within 24 h after TPE and were mild (bleeding rate 1.4% per consecutive daily TPE and 6.1% per patient).


Conclusions
Our findings indicate that patients with low bleeding risk receiving up to five consecutive daily TPE using exclusively albumin replacement fluid without empiric coagulation testing (including fibrinogen testing) or fibrinogen supplementation experience only rare and mild bleeds.
Topics

No keywords indexed for this article. Browse by subject →

References
27
[6]
Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures

Y. L. Chee, J. C. Crawford, H. G. Watson et al.

British Journal of Haematology 10.1111/j.1365-2141.2007.06968.x
[7]
A British Society for Haematology guideline on the assessment and management of bleeding risk prior to invasive procedures

Will Lester, Clare Bent, Raza Alikhan et al.

British Journal of Haematology 10.1111/bjh.19360
[9]
National Cancer Institute U.S. Department of Health and Human Services.Common Terminology Criteria for Adverse Events (CTCAE) v5.0. [cited 2020 Jan 3]. Available from:https://dctd.cancer.gov/research/ctep‐trials/for‐sites/adverse‐events/ctcae‐v6.pdf
[10]
Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia

Kristin Zeidler, Kornelius Arn, Oliver Senn et al.

Transfusion 10.1111/j.1537-2995.2011.03147.x
[11]
Platelet Transfusion before CVC Placement in Patients with Thrombocytopenia

Floor L.F. van Baarle, Emma K. van de Weerdt, Walter J.F.M. van der Velden et al.

New England Journal of Medicine 10.1056/nejmoa2214322
[12]
Medical Advisory Team New Mexico Department of Health.Supplement of the New Mexico crisis standards of care plan. Available from:https://cv.nmhealth.org/wp-content/uploads/2020/05/NM-CSC-Plan-V.5.1.20.pdf
[24]
Baarle FLF "Contribution of coagulopathy on the risk of bleeding after central venous catheter placement in critically ill thrombocytopenic patients" Crit Care Explor (2022)
Metrics
1
Citations
27
References
Details
Published
Mar 23, 2026
License
View
Cite This Article
Jay S. Raval, Joseph R. Griggs, Andres E. Mindiola Romero, et al. (2026). Multiple consecutive daily therapeutic plasma exchange using exclusively albumin replacement fluid in low bleeding risk patients is associated with only rare and mild bleeds. Transfusion. https://doi.org/10.1111/trf.70159